每股分配比例：南微医学科技股份有限公司（以下简称"公司"）本年 度 A 股每 10 股派发现金红利 10.00 元（含税）。不进行公积金转增股本，不送 红股。 证券代码：688029 证券简称：南微医学 公告编号：2025-013 南微医学科技股份有限公司 关于2024年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次利润分配以实施权益分派股权登记日登记的总股本扣减公司回购专 用证券账户中的股份为基数，具体日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股分 配比例不变，相应调整分配总额，并将另行公告具体调整情况。 公司未触及《上海证券交易所科创板股票上市规则（2024 年 4 月修订）》 第 12.9.1 条第一款第（八）项规定的可能被实施其他风险警示的情形。 一、利润分配方案内容 （一）利润分配方案的具体内容 经公证天业会计师事务所（特殊普通合伙）审计，截至2024年12月31日， 母公司期末可供分配利润为人民币1,541,665,6 ...

公证天业经 " 录 Ti 1、募集资金存放与使用情况鉴证报告 2、2024年度募集资金存放与使用情况的专项报告 3、事务所营业执照复印件 4、事务所执业证书复印件 5、签字注册会计师资质证明复印件 公证天业会计师事务所(特殊普通合伙) Gongzheng Tianye Certified Public Accountants, SGP 中国,江苏,无锡 之机:86 (510) 68798988 传真:86(510)68567788 电子信箱:mail@gztycpa.cn 南微医学科技股份有限公司 2024年度募集资金存放与使用情况 专项报告的鉴证报告 苏公 W[2025]E1309 号 Wuxi. Jiangsu. China Tel: 86 (510) 68798988 Fax: 86 (510) 68567788 E-mail: mail@gztycpa.cn 募集资金存放与使用情况鉴证报告 2000000 南微医学科技股份有限公司全体股东: 我们接受委托,对后附的南微医学科技股份有限公司(以下简称"南微医 学")《2024年度募集资金存放与使用情况的专项报告》(以下简称"募集资金专 项报告")进行了鉴 ...

南京证券股份有限公司 关于南微医学科技股份有限公司 募投项目结项并将节余募集资金永久补充流动资金 之核查意见 南京证券股份有限公司（以下简称"南京证券"或"保荐机构"）作为南 微医学科技股份有限公司（以下简称"南微医学"、"发行人"或"公司"） 首次公开发行股票的保荐机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监 管指引第 1 号——规范运作》和《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求》等法律法规和规范性文件的要求，对南微医学募 投项目结项并将节余募集资金永久补充流动资金事项进行了审慎核查，具体核 查情况如下： 一、本次募集资金基本情况 公司本次结项的"国内外研发及实验中心建设项目"已建设完毕并达到预 定可使用状态。截至 2024 年 12 月 31 日，本次结项的募集资金投资项目具体使 用及节余情况如下： 单位：万元 根据中国证券监督管理委员会于 2019 年 7 月 2 日出具的《关于同意南京微 创医学科技股份有限公司首次公开发行股票注册的批复》（证监许可[2019]1178 号），公司获准向社会首次公开发 ...

南微医学科技股份有限公司 审计报告 苏公 W[2025]A693 号 公证天业会计师事务所(特殊普通合伙) Gongzheng Tianye Certified Public Accountants, SGP | 19 17 | | --- | | 1 | | 1、 审计报告 | | --- | | 2、 资产负债表 . | | 3、 利润表 . | | 4、 现金流量表 . | | 5、 所有者权益变动表 | | 6、 财务报表附注 | | 7、事务所营业执照复印件 | | 8、事务所执业证书复印件 | | 9、签字注册会计师资质证明复印件 | 公证天业会计师事务所(特殊普通合伙) Gongzheng Tianye Certified Public Accountants, SGP | 中国. 江苏, 元锡 | | --- | | 总机:86(510)68798988 | | 传真:86(510) 68567788 | | 电子信箱:mail@gztycpa.cn | Wuxi. Jiangsu. China Tel: 86 (510) 68798988 Fax: 86 (510) 68567788 E-m ...

南微医学科技股份有限公司 2024年度内部控制审计报告 苏公 W[2025]E1311 号 公证天业会计师事务所(特殊普通合伙) Gongzheng Tianye Certified Public Accountants, SGP 目 | 1、内部控制审计报告 . | | --- | | 2、内部控制评价报告 | | 3、事务所营业执照复印件 | | 4、事务所执业证书复印件 | | 5、签字注册会计师资质证明复印件 | 公证天业会计师事务所(特殊普通合伙) Gongzheng Tianye Certified Public Accountants, SGP | 江苏 元锡 总机:86 (510) 68798988 86 (510) 68567788 信箱: mail@gztycpa.cn Wuxi. Jiangsu. China Tel: 86 (510) 68798988 Fax: 86 (510) 68567788 E-mail: mail@gztycpa.cn 内部控制审计报告 南微医学科技股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们 审计了南微医学科技 ...

南微医学科技股份有限公司 非经营性资金占用及其他关联资金往 来情况的专项说明 苏公 W[2025]E1310 号 公证天业会计师事务所(特殊普通合伙) Gongzheng Tianye Certified Public Accountants, SGP 公i 目 录 1、非经营性资金占用及其他关联资金往来情况的专项说 明 2、非经营性资金占用及其他关联资金往来情况汇总 表 3、事务所营业执照复印件 4、事务所执业证书复印件 5、签字注册会计师资质证明复印件 公证天业会计师事务所(特殊普通合伙) Gongzheng Tianye Certified Public Accountants, SGP 关于南微医学科技股份有限公司 非经营性资金占用及其他关联资金往来情况的专 南微医学科技股份有限公司全体股东: 我们接受委托,按照中国注册会计师审计准则审计了南微医学科技股份有限公 司(以下简称"南微医学")财务报表,包括2024年12月31日的合并及母公司资 产负债表,2024年度的合并及母公司利润表、合并及母公司现金流量表、合并及母 公司所有者权益变动表以及相关财务报表附注,并于 2025年 4 月 28 日出具了苏 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 699,156,940.30, representing a 12.75% increase compared to CNY 620,078,643.58 in the same period last year[4] - Net profit attributable to shareholders was CNY 160,936,939.70, up 12.18% from CNY 143,464,442.08 year-on-year[4] - The basic and diluted earnings per share were both CNY 0.86, representing a 13.16% increase from CNY 0.76 in the same period last year[4] - Net profit for Q1 2025 was ¥167,162,271.01, representing a 13.36% increase from ¥147,454,778.74 in Q1 2024[19] - Basic and diluted earnings per share for Q1 2025 were both ¥0.86, compared to ¥0.76 in Q1 2024[20] - Other comprehensive income after tax for Q1 2025 was ¥9,159,697.47, compared to a loss of ¥4,059,448.59 in Q1 2024[20] Cash Flow - The net cash flow from operating activities increased by 26.63%, reaching CNY 70,567,097.65 compared to CNY 55,725,577.73 in the previous year[4] - Cash generated from operating activities in Q1 2025 was ¥739,607,987.83, an increase from ¥661,872,530.42 in Q1 2024[21] - The net cash flow from operating activities was $70,567,097.65, an increase of 26.67% compared to $55,725,577.73 in the previous period[22] - The ending balance of cash and cash equivalents was $1,854,972,301.38, up from $911,582,949.17 in the previous period[23] Assets and Liabilities - The total assets at the end of the reporting period were CNY 4,931,235,488.59, reflecting a 3.17% increase from CNY 4,779,606,949.81 at the end of the previous year[5] - The company's current assets totaled RMB 3,223,440,427.41, down from RMB 3,320,779,018.70 at the end of 2024, indicating a decrease of approximately 2.9%[14] - The company's total liabilities decreased to RMB 707,067,941.17 from RMB 806,488,497.71, representing a reduction of approximately 12.3%[15] - The total liabilities decreased to ¥788,040,181.59 in the latest report from ¥880,243,496.13[16] - Total equity attributable to shareholders increased to ¥3,994,462,762.08 from ¥3,826,092,661.23[16] Research and Development - Research and development expenses totaled CNY 38,058,328.95, a 23.09% increase from CNY 30,920,136.25, accounting for 5.44% of operating revenue[5] - Research and development expenses for Q1 2025 were ¥38,058,328.95, up from ¥30,920,136.25 in Q1 2024, indicating a focus on innovation[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,313[8] - The largest shareholder, Shenzhen Zhongke Investment Co., Ltd., held 22.23% of the shares, totaling 41,752,818 shares[8] Non-Recurring Items - The company reported a non-recurring loss of CNY 136,954.02, primarily due to various non-operating income and expenses[6] Investments - The long-term equity investments increased to RMB 63,442,686.57 from RMB 59,795,713.32, showing an increase of about 6.8%[14] - The company reported a significant increase in investment income to ¥3,567,616.18 from ¥2,803,690.30 year-over-year[19] Inventory and Receivables - The inventory value increased to RMB 615,988,795.17 from RMB 536,582,311.14, reflecting a growth of about 14.8%[14] - The company's accounts receivable rose to RMB 523,438,259.11 from RMB 434,035,954.27, marking an increase of about 20.6%[14] Employee Compensation - The company reported a decrease in employee compensation payable from RMB 144,064,326.06 to RMB 72,217,987.56, a reduction of approximately 50.1%[15] - Payments to employees amounted to $270,913,522.63, slightly up from $262,629,113.36 in the previous period[22] Future Outlook - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[23]

Financial Performance - In 2024, the company achieved a historical high in both revenue and profit, with overseas revenue accounting for nearly 50% and US business revenue contributing about 20% of total revenue[11][12]. - The total cash dividend for the year amounted to CNY 280,483,350, representing 50.70% of the net profit attributable to shareholders[5]. - The company plans to distribute a cash dividend of CNY 10.00 per 10 shares, with a total proposed distribution of CNY 186,941,100 based on the adjusted share capital[4]. - The company has implemented a share buyback amounting to CNY 60,001,697.58, with total cash dividends and buyback amounting to CNY 340,485,047.58, which is 61.55% of the net profit attributable to shareholders[5]. - The company reported a significant increase in revenue, achieving a total of RMB 1.5 billion for the fiscal year, representing a year-over-year growth of 25%[20]. - The company's operating revenue for 2024 reached ¥2,755,434,907.16, representing a year-on-year growth of 14.26% compared to ¥2,411,468,385.36 in 2023[27]. - Net profit attributable to shareholders increased by 13.85% to ¥553,226,633.36 in 2024, up from ¥485,924,270.19 in 2023[27]. - Basic earnings per share rose to ¥2.95, a 13.90% increase from ¥2.59 in the previous year[28]. - The gross margin for the year improved to 60%, up from 55% in the previous year, reflecting better cost management and pricing strategies[20]. Research and Development - The company aims to enhance its research and development capabilities, particularly in clinical techniques and core technologies, to strengthen its competitive edge[12]. - The company has invested RMB 200 million in R&D for advanced medical technologies, aiming to improve product efficacy and safety[20]. - Research and development expenses accounted for 6.33% of operating revenue, slightly up from 6.25% in 2023[28]. - R&D investment reached 174 million RMB, accounting for 6.33% of revenue, with significant product registrations and innovations, including the first domestic registration for a pancreatic cyst drainage stent[36]. - The company has received multiple national science and technology awards, including the National Science and Technology Progress Award for the development of new digestive tract stents and the application of microwave ablation devices[58]. - The company is actively developing a deep learning algorithm for automatic labeling of esophageal abnormal image features, which will be integrated into existing imaging software[57]. - The company has a cumulative total of 904 patent applications, with 656 patents granted[61]. Market Expansion and Strategy - The company is actively pursuing market expansion in Southeast Asia, targeting a 15% market share within the next two years[20]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 20% to 30% based on new product launches and market expansion strategies[20]. - The company is committed to exploring AI applications in healthcare, aligning with the recent guidelines issued by the National Health Commission[14]. - The company is focused on continuous innovation and collaboration with academic and medical institutions to mitigate risks in product development[77]. - The company plans to enhance its international strategy by expanding into emerging overseas markets while strengthening domestic sales[79]. - The company is considering strategic acquisitions to enhance its product portfolio and market presence[150]. - The company plans to establish a European regional headquarters and an Australian representative office in 2024[161]. Operational Efficiency and Cost Management - The company is focusing on lean operations and cost reduction, achieving significant improvements in operational efficiency and quality management[38]. - The company emphasizes cost control to enhance production efficiency and maintain competitive pricing[73]. - Operating costs for the main business increased by 4.31% to 883.85 million RMB, primarily due to revenue growth[87]. - The gross profit margin improved by 3.13 percentage points compared to the previous year, driven by cost reduction initiatives and stable product structure[92]. - The company has implemented cost-cutting measures that are expected to save approximately $10 million annually[152]. Governance and Compliance - The company maintained robust investor relations, providing timely and accurate disclosures through designated media channels[142]. - The company has established a comprehensive internal control system, ensuring compliance with relevant laws and regulations, with no significant internal control deficiencies reported during the period[188]. - The company’s governance structure remains compliant with relevant laws and regulations, ensuring effective oversight[146]. - The company has established various specialized committees, including the Audit Committee and the Strategic Committee, to enhance governance[165]. - The company has not faced any penalties from securities regulatory agencies in the past three years[160]. Sustainability and Social Responsibility - The company invested 1.31 million yuan in environmental protection initiatives during the reporting period[195]. - The company achieved an ESG rating of AAA from Zhongzheng Index and AA from Wind ESG, indicating strong performance in environmental, social, and governance practices[193]. - The company reported a total greenhouse gas emissions of 401.56 tons of CO2 equivalent for Scope 1 and 8,834.58 tons for Scope 2 during the year[199]. - The company actively participates in national procurement initiatives to reduce patient costs and improve medical accessibility[192]. - The company has made significant efforts in promoting sustainable development through its operations and product lifecycle management[192].

南微医学科技股份有限公司 2024 年度独立董事述职报告 吴应宇 2024年度,作为南微医学科技股份有限公司(以下简称"公司")的独立董 事,本人严格按照《公司法》《证券法》《上市公司治理准则》《上海证券交易所 科创板股票上市规则》《上市公司独立董事规则》以及《公司章程》《独立董事工 作制度》等法律、法规规定,积极出席公司股东大会、董事会及专门委员会会议, 针对重大事项召开独立董事专门会议进行审议,发挥自身专业特长,为公司经营 发展提出合理化建议,勤勉、尽责、独立地履行独立董事的职责,推动公司稳健、 规范、可持续发展,切实维护公司全体股东尤其是中小股东的合法权益。现将 2024年度履行职责情况报告如下: 一、 独立董事基本情况 2024 年公司董事会由9名董事组成,其中独立董事3人,占董事会人数三 分之一,符合相关法律法规中关于上市公司独立董事人数比例和专业配置的规定。 2024年8月9日公司召开2024年第二次临时股东大会,完成第四届董事会换届 选举,吴应宇先生、解亘先生、万遂人先生继续担任公司独立董事。 (一)个人履历 吴应宇,1982年2月至1988年6月在南京工学院(现东南大学)党委办公 室工作,任秘 ...

南微医学科技股份有限公司 2024 年度独立董事述职报告 一、 独立董事基本情况 2024 年公司董事会由 9 名董事组成,其中独立董事 3 人,占董事会人数三 分之一,符合相关法律法规中关于上市公司独立董事人数比例和专业配置的规定。 2024 年 8 月 9 日公司召开 2024 年第二次临时股东大会,完成第四届董事会换届 选举,吴应宇先生、解亘先生、万遂人先生继续担任公司独立董事。 (一)个人履历 解亘,男,1967年出生,中国国籍,无境外永久居留权,法学博士,南京大 学法学院教授,博士生导师。现任江苏省农垦农业发展股份有限公司(2025年1 月离任)、江苏太平洋石英股份有限公司独立董事。2022年 12 月至今,任本公 司独立董事。 (二) 独立董事任职董事会专门委员会情况 本人在公司董事会薪酬与考核委员会任职主任委员,在公司董事会审计委员 会任职委员。 解目 (三) 独立性说明 2024年度,作为南微医学科技股份有限公司(以下简称"公司")的独立董 事,本人严格按照《公司法》《证券法》《上市公司治理准则》《上海证券交易所 科创板股票上市规则》《上市公司独立董事规则》以及《公司章程》《独立董事工 作制度 ...